10-Q: OS Therapies Q2 Loss Widens Amid R&D Surge, New Funding

OS Therapies reported a significantly wider net loss in Q2 2025, driven by increased R&D and administrative costs, while securing new capital and advancing its lead cancer immunotherapy.

Summary

• Net loss for the six months ended June 30, 2025, was $8.41 million, a substantial increase from $3.02 million for the same period in 2024.
• Research and Development (R&D) expenses surged to $3.81 million for the six months ended June 30, 2025, up from $0.76 million in the prior year, primarily due to Phase IIb clinical trial preparation and advisor fees.
• General and Administrative (G&A) expenses increased significantly to $6.03 million for the six months ended June 30, 2025, compared to $0.65 million in 2024, mainly due to marketing, investor relations, and advisory fees related to financing activities.
• The company acquired HER2 and Lm-related intellectual property assets from Ayala Pharmaceuticals, Inc. for $8 million, consisting of $0.5 million in cash and $7.5 million in common stock and warrants.
• This acquisition terminated the previous license agreement with Ayala, eliminating future milestone payments totaling $20 million and reducing royalty rates on net sales from 10% to 1.5% (payable to the University of Pennsylvania).
• OS Therapies received positive written feedback from the FDA regarding its Phase IIb trial design for OST-HER2 and has submitted a Breakthrough Therapy Designation request.
• The company completed a PIPE financing in late 2024 and early 2025, raising approximately $7.1 million in gross proceeds from the issuance of Series A Preferred Stock and Series A Warrants.
• A warrant exercise inducement and exchange offer, completed on July 11, 2025, generated approximately $4.22 million in gross proceeds.
• As of June 30, 2025, cash on hand was $2.80 million, down from $5.53 million at December 31, 2024.
• The company has an accumulated deficit of $46.85 million as of June 30, 2025, indicating significant historical losses.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to limited personnel and insufficient written policies.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significantly widening losses, increased cash burn, a declining cash balance, and explicit 'going concern' doubt. While there are positive clinical and strategic advancements, the immediate financial health and internal control deficiencies present significant concerns for investors.

Positives

• Received positive written feedback from the FDA on the design and endpoints of the Phase IIb trial for OST-HER2, supporting a potential Biologics License Application (BLA).
• Submitted a Breakthrough Therapy Designation request for OST-HER2, which could expedite development and review.
• Acquired HER2 and Lm-related assets from Ayala Pharmaceuticals, Inc., eliminating $20 million in future milestone payments and reducing royalty obligations from 10% to 1.5% of net sales.
• Successfully completed a PIPE financing, raising approximately $7.1 million in gross proceeds.
• Successfully completed a warrant exercise inducement and exchange offer, raising an additional approximately $4.22 million in gross proceeds.
• Formed OS Animal Health Corp, a wholly-owned subsidiary, to advance strategic alternatives for animal health applications of its technology.
• Filed a registration statement on Form S-3 for future offerings of up to $100 million in securities, including an 'at the market' offering for up to $18 million of common stock, providing future capital access.

Negatives

• Net loss significantly widened to $8.41 million for the six months ended June 30, 2025, compared to $3.02 million in the prior year.
• Operating expenses, including R&D and G&A, increased substantially, indicating a higher cash burn rate.
• Cash balance decreased to $2.80 million as of June 30, 2025, from $5.53 million at December 31, 2024.
• Accumulated deficit grew to $46.85 million, reflecting ongoing losses since inception.
• Management identified a material weakness in internal controls, specifically a lack of segregation of duties due to limited personnel and insufficient written policies and procedures for accounting, information technology, and financial reporting.
• The company's ability to continue as a going concern raises substantial doubt due to incurred net losses and negative operating cash flows since inception.
• Significant dilution occurred from common stock issuances related to PIPE conversions, warrant exercises, and the HER2 asset purchase, with potential for further dilution from future offerings.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to accumulated losses and negative operating cash flows.
• The company is dependent on its ability to obtain additional capital through public or private financing, with no assurances of success.
• Future issuances of common stock or other convertible securities could result in substantial dilution to existing stockholders and negatively affect the market price.
• Sales by selling stockholders of a significant number of shares, or the perception of such sales, could adversely affect the common stock's trading price.
• Internal control deficiencies, including lack of segregation of duties and insufficient written policies, could adversely affect the company's ability to record, process, summarize, and report financial information reliably.
• The company's net operating loss (NOL) carryforwards and R&D tax credit carryforwards may be limited or expire unused due to Section 382 and 383 of the Internal Revenue Code.

Future Outlook

The company plans to submit a Biologics License Application (BLA) for OST-HER2 following an End of Phase 2 meeting with the FDA, anticipated in the third quarter of 2025, subject to continued positive regulatory guidance. It intends to evaluate OST-HER2's potential use, alone and in combination with HER2 targeting antibodies, in other solid tumors like breast, esophageal, and lung cancers. The company also plans to investigate clinical indications for its OST-tADC platform in Osteosarcoma and other solid tumors, initiate AI-driven next-generation tADC product candidate modeling, and close out and report on its OST-504 prostate cancer study. Net proceeds from recent offerings will support U.S. and international regulatory and pre-commercial efforts for OST-HER2 and advance the OS Animal Health subsidiary.

Management Comments

• We are currently seeking to answer the call for new treatments that will prevent metastasis and the recurrence of metastases with our lead core product candidate OST-HER2.
• Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
• We intend to investigate clinical indications for OST-tADC in Osteosarcoma and other solid tumors, furthering our founding mission.

Industry Context

OS Therapies operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on oncology, with a niche in Osteosarcoma and other solid tumors. The company's development of OST-HER2, a cancer immunotherapy, aligns with the growing trend of immune-oncology treatments. The acquisition of HER2 and Lm-related assets, including IND filings for non-small cell lung cancer and prostate cancer, indicates a strategic expansion beyond its initial focus. The exploration of Tunable Drug Conjugate (tADC) technology also positions the company within the advanced drug delivery and targeted therapy segment of the industry, which is a rapidly evolving area.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards. Performance metrics are presented on a standalone basis.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently in arbitration for a claim brought by its former investment advisor for underwriter compensation related to the company's initial public offering in August 2025. The company believes the claim is meritless.

Related Party Transactions

• Payroll payable to CEO Paul Romness was $0 as of June 30, 2025, with all related advances repaid in 2025.
• Accounting fees of $19,365 for the six months ended June 30, 2025, were paid to Shore Accountants MD Inc., an outside accounting firm 100% owned by Christopher Acevedo, the CFO.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future equity issuances, which could negatively impact share price.
• Patients with Osteosarcoma and other solid tumors may benefit from the continued development and potential commercialization of OST-HER2 and OST-tADC.
• Employees are impacted by stock-based compensation and the company's ongoing financial challenges and internal control issues.
• Creditors (former convertible note holders) have had their debt converted to common stock, altering their investment position.

Next Steps

• Conduct an End of Phase 2 meeting with the FDA, anticipated in Q3 2025.
• Submit a Biologics License Application (BLA) for OST-HER2 following positive regulatory guidance.
• Evaluate OST-HER2's potential use, alone and in combination with HER2 targeting antibodies, in other solid tumors (breast, esophageal, lung cancers).
• Advance strategic alternatives for the OS Animal Health subsidiary.
• Close out and report on the OST-504 (previously ADXS-504) prostate cancer study.
• Initiate AI-driven next-generation tADC product candidate modeling.
• Keep the Resale Registration Statement (Form S-3) effective until no New Warrants or New Warrant Shares are outstanding or the Delegend Date.

Key Dates

Recommendation

While OS Therapies faces significant financial challenges, including widening losses, declining cash, and a 'going concern' warning, the company has successfully raised new capital and made notable progress in its clinical development, particularly with positive FDA feedback for OST-HER2 and the strategic acquisition of HER2 assets. The high burn rate and internal control issues are concerning, but the potential for Breakthrough Therapy Designation and a BLA submission for OST-HER2, along with the development of the OST-tADC platform, offer long-term upside. For a seasoned investor, the current situation presents a high-risk, high-reward scenario. A 'hold' recommendation acknowledges the substantial risks while recognizing the ongoing clinical advancements and recent capital infusions that provide a lifeline for continued operations and potential future value creation, warranting close monitoring rather than immediate divestment.

Keywords

Osteosarcoma, Cancer Immunotherapy, Biopharmaceutical, HER2, Clinical Trial, Oncology, Biotech, SEC Filing, 10-Q, OST-HER2, ADXS-503, ADXS-504, Tunable Drug Conjugate, ADC, FDA, BLA